AbbVie demonstrated strong commercial, operational, and R&D execution with significant growth from its ex-HUMIRA platform, increased revenue and EPS guidance, and successful acquisition and integration of Cerevel Therapeutics. However, challenges remain with declining HUMIRA sales, aesthetic market headwinds, and competitive pressures on IMBRUVICA.

Company Guidance

During AbbVie's Q3 2024 earnings call, the company reported sales exceeding expectations by $260 million, with operational sales growth in the mid-single digits, driven by an 18% increase in the ex-HUMIRA platform. Key products, including SKYRIZI and RINVOQ, are expected to generate over $17 billion in combined sales, surpassing initial forecasts by $1.3 billion. The company raised its full-year revenue guidance by $500 million, marking a total increase of $1.8 billion since February, and adjusted EPS guidance by $0.15, now anticipated between $10.90 and $10.94. AbbVie also highlighted significant advancements in its pipeline, including the acquisition of Cerevel Therapeutics and positive Phase III results for Tavapadon in Parkinson's disease. Additionally, they announced a 5.8% increase in their quarterly cash dividend, reflecting more than a 300% rise since inception.

Strong Performance and Growth from Ex-HUMIRA Platform

AbbVie's diversified portfolio delivered sales $260 million above expectations, driven by nearly 18% growth from the ex-HUMIRA platform. SKYRIZI and RINVOQ combined sales are expected to exceed $17 billion this year, $1.3 billion above initial expectations.

Increased Revenue and EPS Guidance

AbbVie raised its full-year revenue guidance by $500 million and adjusted EPS guidance by $0.15. The company now expects adjusted EPS between $10.90 and $10.94.

Successful Acquisition and Integration of Cerevel Therapeutics

The acquisition of Cerevel Therapeutics has strengthened AbbVie's neuroscience pipeline, with positive Phase III results for Tavapadon in Parkinson's and progress in schizophrenia studies.

Dividend Increase

AbbVie announced a 5.8% increase in its quarterly cash dividend, marking a cumulative increase of over 300% since inception.

Robust Sales Growth in Immunology

Immunology sales exceeded $7 billion, with SKYRIZI global sales up 51.5% and RINVOQ sales up 47.4%, driven by strong prescription growth across multiple indications.

Oncology and Neuroscience Growth

VENCLEXTA sales rose 18.2%, and VRAYLAR sales increased by 16.6%. The launch of new therapies like Violav for Parkinson's and approvals for BOTOX in new indications also contributed to growth.

---

AbbVie (ABBV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ABBV Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jan 29, 2025	2024 (Q4)	2.98 / -	2.79	―	―	―
Oct 30, 2024	2024 (Q3)	2.92 / 3.00	2.95	1.69% (+0.05)	―
Jul 25, 2024	2024 (Q2)	2.57 / 2.65	2.91	-8.93% (-0.26)	―
Apr 26, 2024	2024 (Q1)	2.25 / 2.31	2.46	-6.10% (-0.15)	―
Feb 02, 2024	2023 (Q4)	2.79 / 2.79	3.6	-22.50% (-0.81)
Oct 27, 2023	2023 (Q3)	2.87 / 2.95	3.66	-19.40% (-0.71)	―
Jul 27, 2023	2023 (Q2)	2.83 / 2.91	3.37	-13.65% (-0.46)	―
Apr 27, 2023	2023 (Q1)	2.51 / 2.46	3.16	-22.15% (-0.70)	―
Feb 09, 2023	2022 (Q4)	3.56 / 3.60	3.31	8.76% (+0.29)
Oct 28, 2022	2022 (Q3)	3.57 / 3.66	3.33	9.91% (+0.33)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

ABBV Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 30, 2024	$189.45	$201.50	+6.36%
Jul 25, 2024	$174.81	$180.73	+3.39%
Apr 26, 2024	$164.45	$156.91	-4.58%
Feb 02, 2024	$163.22	$164.28	+0.65%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---